Considerable evidence suggests that all RTN proteins and receptor NgR are engaged in the pathology change of AD by regulating the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) function or APP processing, and thereby product amyloid β in the brain (Kulczynska-Przybik et al., 2021). This evidence concerns the gene APP and Alzheimer disease.